Kinetics of human thrombin inhibition by two novel peptide inhibitors (Hirunorm IV and Hirunorm V)

Biochemical Pharmacology

Volumn 52, Issue 8, 1996, Pages 1141-1146

  Cappiello, Mario ^a   Vilardo, Pier Giuseppe ^a   Lippi, Annalisa ^b   Criscuoli, Marco ^b   Del Corso, Antonella ^a   Mura, Umberto ^c,d  

^a UNIVERSITY OF PISA   (Italy)

^b Laboratori Guidotti SpA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d Dipto di Fisiologia e Biochimica   (Italy)

Author keywords

coagulation; hirudin; Hirulog; Hirunorm; thrombin; thrombin inhibition

Indexed keywords

FIBRINOGEN; HIRULOG; HIRUNORM IV; HIRUNORM V; LEPIRUDIN; NEW DRUG; PEPTIDE DERIVATIVE; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CHROMOZYM TH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION CONSTANT; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE; HUMAN; HYDROLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0030601880     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00388-7     Document Type: Article

References (27)

1. 1. Tapparelli C, Metternich R, Ehrhardt C and Cook NS, Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. TIPS 14: 366-376, 1993.
2. 2. Lundblad RL, Kingdon HS and Mann KG, Thrombin. In: Methods Enzymol Vol. 45 (Ed. Lorand L) pp. 156-176. Academic Press, New York, 1976.
3. 3. Fenton JW II, Thrombin specificity. Ann NY Acad Sci 370: 468-495, 1981.
4. 4. Fenton JW II, Olson TA, Zabinski MP and Wilner GD, Anion-binding exosite of human α-thrombin and fibrin(ogen) recognition. Biochemistry 27: 7106-7112, 1988.
5. 5. Bode W, Turk D and Karshikov A, The refined 1.9-Angstrom X-ray crystal structure of D-Phe-Pro-Arg-Chloromethylketone-inhibited human α-thrombin - Structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationship. Protein Sci 1: 426-471, 1992.
6. 6. Olson ST and Shore JD, Demonstration of a two-step reaction mechanism for inhibition of α-thrombin by antithrombin III and identification of the step affected by heparin. J Biol Chem 257: 14891-14895, 1982.
7. 7. Markwardt F, Hirudin as an inhibitor of thrombin. In: Methods Enzymol Vol. 19 (Eds. Perlmann GE and Lorand L) pp. 924-932. Academic Press, New York, 1970.
8. 8. Stone SR and Hofsteenge J, Kinetics of the inhibition of thrombin by hirudin. Biochemistry 25: 4622-4628, 1986.
9. 45-65. J Biol Chem 265: 21698-21703, 1990.
10. 10. Maranagore JM, Bourdon P, Jablonski J, Ramachandran KL and Fenton JW II, Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29: 7095-7101, 1990.
11. 11. Witting JI, Bourdon P, Brezniak DV, Maranagore JM and Fenton JW II, Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J 283: 737-743, 1992.
12. 12. Witting JI, Bourdon P, Maranagore JM, and Fenton JW II, Hirulog-1 and -B2 thrombin specificity. Biochem J 287: 663-664, 1992.
13. 13. Maranagore JM, Hirudin and hirulog: advances in antithrombotic therapy. Perspect Drug Discovery Design 1: 461-478, 1993.
14. 14. Chase T Jr and Shaw E, Comparison of the esterase activities of trypsin, plasmin, and thrombin on guanidinobenzoate esters. Titration of the enzymes. Biochemistry 8: 2212-2224, 1969.
15. 15. Fenton JW II, Fasco MJ, Stackrow AB, Aronson DL, Young AM and Finlayson JS, Human thrombin - Production, evaluation and properties of α-thrombin. J Biol Chem 252: 3587-3598, 1977.
16. 16. Lottenberg R, Christensen U, Jackson CM and Coleman PL, Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. In: Methods Enzymol Vol. 80 (Ed. Lorand L) pp. 341-361. Academic Press, New York, 1981.
17. 17. Morrison JF, Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta 185: 269-286, 1969.
18. 18. Henderson PJF, Steady-state enzyme kinetics with high-affinity substrates or inhibitors. Biochem J 127: 321-333, 1972.
19. 19. Fenton JW II, Witting JI, Pouliott C and Fareed J, Thrombin anion-binding exosite interaction with heparin and various polyanions. Ann NY Acad Sci 556: 158-165, 1989.
20. 20. Higgins DL, Lewis SD and Shafer JA, Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin. J Biol Chem 258: 9276-9282, 1983.
21. 21. Cha S, Tight-binding inhibitors-III. A new approach for the determination of competition between tight-binding inhibitors and substrates - Inhibition of adenosine deaminase by coformicin. Biochem Pharmacol 25: 2695-2702, 1976.
22. 22. Williams JW and Morrison JF, The kinetics of reversible tight-binding inhibition. In: Methods Enzimol Vol. 63 (Ed. Purich DL) pp. 437-467. Academic Press, New York, 1979.
23. 23. Laemmli UK, Cleavage of structural proteins during the assembly of the head of the bacteriofage T-4. Nature 227: 680-685, 1970.
24. 24. Wray W, Boulikas T, Wray VP and Hancock R, Silver staining of proteins in polyacrylamide gels. Anal Biochem 118: 197-203, 1981.
25. 25. Cha S, Tight-binding inhibitors - I. Kinetic behaviour. Biochem Pharmacol 24: 2177-2185, 1975.
26. 26. DeCristofaro R, Fenton JW and DiCera E, Modulation of thrombin-hirudin interaction by specific ion effects. J Mol Biol 226: 263-269, 1992.
27. 27. Cirillo R, Lippi L, Subissi A, Agnelli G and Criscuoli M, Experimental pharmacology of Hirunorm: a novel synthetic peptide thrombin inhibitor. Thromb Haemost (in press).